HMGCR and type 2 diabetes mellitus: This is easily explained by the fact that 57% of the T2DM patients, as compared to 13% of control and 25% of preDM, were on a HMG-CoA reductase medication at the time, which is used clinically to decrease serum LDL levels and reduce cardiovascular events.